Sign in
Taking people in United StatesNo phase

Compares two immune drug combinations in advanced melanoma, studying blood and tumor responses

Studies immune responses in blood and tumor of adults with advanced melanoma.

Key facts

Who runs it
John Kirkwood
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Status
Recruiting
People taking part
20 people, planned
Started
19 Nov 2025
Expected to end
1 Nov 2031
Type of study
Observational, 2 groups
Treatments tested
  • Fianlimab + Cemiplimab
  • Relatlimab + Nivolumab
Record updated
26 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that cannot be removed by surgery or has spread, who are already in the HCC 24-056 study and agree to give extra tumor and blood samples.

Age
18 years or older
Sex
All sexes can join
Disease stage
Melanoma that cannot be removed by surgery (locally advanced) or has spread (metastatic), with tumor spots that can be biopsied at least 3 times

Main reasons for not taking part

  • People who do not qualify to enroll in the HCC 24-056 study cannot join

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study
  • Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:; 3 additional tumor biopsies; 3 additional blood draws
  • Participants must have biopsiable non-target disease amenable to at least 3 biopsies
  • Must have the ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study; -

Where in United States

  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Danielle L Bednarz, RNTaking people

About the trial

What the trial wants to find out

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.

The 2 groups in the trial

  • fianlimab + cemiplimab

    Patients who received fianlimab + cemiplimab treatment under protocol NCT06246916.

  • Opdualag (relatlimab + nivolumab)

    Patients who received Opdualag (relatlimab + nivolumab) under protocol NCT06246916.

    Treatment: Relatlimab + Nivolumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)
Plain-language title
Compares two immune drug combinations in advanced melanoma, studying blood and tumor responsesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 November 2025